Randomized Trialhigh evidence
Tozorakimab to Prevent COPD Exacerbations.
The New England journal of medicine·September 8, 2026·PMID 42708515
Why it mattersCOPD exacerbations drive morbidity and mortality, and many patients continue to exacerbate despite maximal inhaled therapy. Tozorakimab offers a novel mechanism targeting IL-33, potentially benefiting a broad population without eosinophil-based selection.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled